Exchange: NYSE·Updated 07:59 PM EDT

ABBV News

News
all
press releases
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb are all pharmaceutical companies that pay quarterly dividends...
Nasdaq News: Markets
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb are all pharmaceutical companies that pay quarterly dividends...
Nasdaq News: Markets
More News
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 8.13% on an annualized basis producing an average annual return of 20.55%. Currently, AbbVie has a market capitalization of $481.85 billion.read more...
Benzinga
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.
Zacks
Why is AbbVie (ABBV) Stock Trending After Hours?
AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.read more...
Benzinga
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Zacks
2026 Brings New Hope in the Fight Against Cancer as Breakthroughs Gather Momentum
NeOnc Technologies (NASDAQ:NTHI), Revolution Medicines (NASDAQ:RVMD), Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Genmab (NASDAQ:GMAB), and AbbVie (NYSE:ABBV) are among the companies contributing to a rapidly evolving cancer-treatment landscape in 2026, as researchers pursue new ways to extend survival, target tumors more precisely and give patients additional treatment options.
24-7 Market News
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCPR NewswireNORTH CHICAGO, Ill., Oct. 7...
PR Newswire
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share...
Nasdaq News: Markets
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.
Zacks

Advertisement|Remove ads.